Symposium:
185. Duration of Antimicrobial Therapy: How Long is Long Enough?
Sunday, October 23, 2011: 7:30 AM-9:00 AM
Room: 210ABC

Learning Objectives:

Upon completion of this session, participants will be able to:

  • describe current evidence from antimicrobial treatment studies examining the impact of duration of therapy on safety and efficacy
  • describe the impact of treatment duration on antimicrobial resistance development
  • discuss antimicrobial study design approaches to address questions regarding the optimal duration of antibiotic drug therapy

Target Audience: Industry, Regulatory Agencies, Researchers, Pharmacists, Microbiologists, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Hospital Administrators, Fellows-in-Training, Clinicians, Academicians

Tracks: Adult ID

Moderators:  Elizabeth Hermsen, PharmD, Cubist and John Rotschafer, Pharm D, University of Minnesota

Presentations:

8:00 AM

8:30 AM
Clinical Trial Design: Future Study Options
John H. Powers III, MD, FIDSA

CME Credits: Maximum of 1.5 hours of Category 1 credit possible

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-117-L01-P

Disclosures:

E. Hermsen, Cubist Pharmaceuticals: Employee and Shareholder, Salary

J. Rotschafer, Cubist: Consultant, Consulting fee
Optimer: Consultant, Consulting fee
Forrest: Consultant, Consulting fee

J. Rotschafer, Cubist: Consultant, Consulting fee
Optimer: Consultant, Consulting fee
Forrest: Consultant, Consulting fee

L. B. Rice, Theradoc/Hospira: Scientific Advisor, Consulting fee
T2: Scientific Advisor, Consulting fee

J. H. Powers III, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.